GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (NAS:ABCL) » Definitions » Intrinsic Value: Projected FCF

AbCellera Biologics (AbCellera Biologics) Intrinsic Value: Projected FCF : $0.00 (As of Jun. 07, 2024)


View and export this data going back to 2020. Start your Free Trial

What is AbCellera Biologics Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-06-07), AbCellera Biologics's Intrinsic Value: Projected FCF is $0.00. The stock price of AbCellera Biologics is $3.62. Therefore, AbCellera Biologics's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for AbCellera Biologics's Intrinsic Value: Projected FCF or its related term are showing as below:

ABCL's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.18
* Ranked among companies with meaningful Price-to-Projected-FCF only.

AbCellera Biologics Intrinsic Value: Projected FCF Historical Data

The historical data trend for AbCellera Biologics's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics Intrinsic Value: Projected FCF Chart

AbCellera Biologics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial - - - - -

AbCellera Biologics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AbCellera Biologics's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, AbCellera Biologics's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbCellera Biologics's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where AbCellera Biologics's Price-to-Projected-FCF falls into.



AbCellera Biologics Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



AbCellera Biologics  (NAS:ABCL) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

AbCellera Biologics's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=3.62/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AbCellera Biologics Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AbCellera Biologics (AbCellera Biologics) Business Description

Traded in Other Exchanges
Address
2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Executives
John S. Montalbano director C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Michael R Hayden director C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Veronique Lecault director, officer: Chief Operating Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Thermopylae Holdings Ltd. 10 percent owner 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Andrew Booth officer: Chief Financial Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Andrew Lo director C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
John Hamer director, 10 percent owner PO BOX 14528, RESEARCH TRIANGLE PARK NC 27709-4528
Ester Falconer officer: Chief Technology Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Hansen Carl L. G. director, 10 percent owner, officer: Chief Executive Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Tryn Stimart officer: Chief Legal Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Peter Thiel director 9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069
Dcvc Bio, L.p. 10 percent owner 317 UNIVERSITY AVENUE, SUITE 200, PALO ALTO CA 94301
Dcvc Bio Gp, Llc 10 percent owner 270 UNIVERSITY AVENUE, PALO ALTO CA 94301
Zachary Bogue 10 percent owner 270 UNIVERSITY AVENUE, PALO ALTO CA 94301
Matthew Ocko 10 percent owner 270 UNIVERSITY AVENUE, PALO ALTO CA 94301